marked.bio

ERK inhibitor · small molecule

ulixertinib

2 active trials across 4 of our biomarkers, targeting ERK1/2. Not approved for any biomarker on marked.bio yet.

Also known as BVD-523.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 2 4 Phase 2
KRAS G12C 0 1 –
KRAS G12D 0 1 –
MSI-H / dMMR 0 1 –

Trials

2 of 6 trials shown

  1. Ulixertinib in People With Histiocytic Neoplasms

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2024Primary completion 2027-05 NCT06411821

    ulixertinib

    Concordance between cfDNA and tumor sequencing for BRAFV600E and non-BRAF mutations in histiocytic neoplasms has been documented by our group and othe…

    BRAF V600EHistiocytic Neoplasms

  2. Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

    Recruiting Phase 1 M.D. Anderson Cancer Center Started 2024Primary completion 2028-03 NCT05985954

    cetuximab FDA EUulixertinibencorafenib FDA EU

    BRAF expansion Cohort: BRAF V600E mutation must be present

    BRAF V600EMetastatic Colorectal Cancer